A bill that would allow the Maryland attorney general to take legal action against generic drug makers for price gouging became law on Friday by default, after Governor Lawrence Hogan Jr. declined to sign the legislation over constitutional concerns.

The outcome was praised by consumer activists, who decried a “Wild West” pricing atmosphere, but lambasted by the generic industry trade association, which maintained the law would have a “chilling” effect on competition and “no material impact” on lowering drug costs in the state.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hmm, I learned that competition leads to LOWER prices and “efficient markets”. Was that a lie? I’m in total shock now!

    Or is there some kind of cartelize market here? Again I’m in total shock!

    One way or the other markets don’t work for pharma. Time for the legislation (and maybe some prosecutors?) to scrub in?

  • Ed, this is classic Whack-A-Mole pharma style. Since most generics are multisource, as soon as Maryland nails one another will emerge.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy